Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 1 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
   
  
Clinical Investigation Plan  
Clinical investigation plan/Study Title  Evaluation of the Valiant Mona LSA Thoracic 
Stent Graft System in Descending Thoracic 
Aortic Aneurysms and Chronic Dissections  
Clinical Investigation Plan Identifier  10151194DOC  
Study Product Name  Valiant Mona LSA Thoracic Stent Graft 
System  
Sponsor/Local Sponsor  Medtronic Vascular, Inc.  
3576 Unocal Place  
Santa Rosa, CA 95403  
Document Version  1F, 22 January  201 9 
IDE Number  G130027  
Lead Principal Investigator(s)  Eric Roselli, MD  
Cleveland Clinic  
Cleveland, OH  
Confidentiality Statement  
The  information  contained  in this  document  is confidential  and  the  proprietary  property  of 
Medtronic.  Any  distribution,  copying,  or disclosure  without  the  prior  written  authorization  of 
Medtronic  is strictly  prohibited.  Persons  to whom  the  information  is disclosed  must  know  that  it 
is confidential  and  that  it may  not  be further  disclosed  by them.  
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 2 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 VERSION HISTORY  
Version  Summary of Changes  Author(s)/Title  
1A Not Applicable, New Document   
 
1B See Appendix J  
 
1C See Appendix K  
 
1D See Appendix L  
 
1E See Appendix M  
 
1F See Appendix N   
 
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 3 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 TABLE OF CONTENTS  
CLINICAL STUDY SYNOP SIS ................................ ................................ ................................ ................................  7 
1. INTRODUCTION  ................................ ................................ ................................ ................................ ..............  21 
2. BACKGROUND  ................................ ................................ ................................ ................................ ................  23 
3. INTENDED USE OF THE DEVICE  ................................ ................................ ................................ ...................  38 
4. DESCRIPTION OF THE D EVICE  ................................ ................................ ................................ .....................  39 
4.1. DEVICE COMPONENTS  ................................ ................................ ................................ ................................  39 
4.2. MAIN STENT GRAFT SYSTEM  ................................ ................................ ................................ .......................  39 
4.3. BRANCH STENT GRAFT SYSTEM  ................................ ................................ ................................ ..................  43 
4.4. DEVICE SIZES AND CONFIGURATIONS  ................................ ................................ ................................ ..........  47 
5. STUDY OBJECTIVES  ................................ ................................ ................................ ................................ ...... 48 
5.1 STUDY PURPOSE  ................................ ................................ ................................ ................................ .........  48 
5.2 SCOPE AND DURATION OF THE CLINICAL STUDY  ................................ ................................ ..........................  48 
6. CLINICAL STUDY DESIG N ................................ ................................ ................................ .............................  49 
7. METHODS AND ANALYSES  ................................ ................................ ................................ ...........................  50 
7.1 DESCRIPTION OF STUDY OBSERVATIONS  ................................ ................................ ................................ ..... 50 
7.1.1  Primary Safety Observation  ................................ ................................ ................................ ................  50 
7.1.2  Primary Effectiveness Observation  ................................ ................................ ................................ .... 50 
7.1.3  Additional Observations  ................................ ................................ ................................ .....................  50 
7.1.4  Periprocedural and Discharge Clinical Utility Measures  ................................ ................................ ..... 52 
7.2 SAMPLE SIZE CALCULATIONS  ................................ ................................ ................................ ......................  52 
7.3 ANALYSIS OF OBSERVATIONS  ................................ ................................ ................................ ......................  52 
7.3.1  Data Analysis Set ................................ ................................ ................................ ................................ . 52 
7.3. 2 Analysis of the Primary Safety Observation  ................................ ................................ .......................  52 
7.3.3  Analysis of the Primary Effectiveness Observation  ................................ ................................ ...........  52 
7.3.4  Analysis of the Additional Observations  ................................ ................................ .............................  53 
7.3.5  Analysis of the Periprocedural through Discharge Clinical Utility Measures  ................................ ..... 53 
7.3.6  Analysis of Baseline Variables  ................................ ................................ ................................ .............  53 
7.3.7  Subset Analyses  ................................ ................................ ................................ ................................ .. 53 
7.3.8  Time Window Conventions Used in Analysis of Observations  ................................ ...........................  54 
7.3.9  Patient Withdrawal and Missing Data  ................................ ................................ ................................ . 55 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 4 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 8. CLINICAL STUDY PREPA RATION PROCEDURES  ................................ ................................ .......................  56 
8.1 SELECTION OF CLINICAL INVESTIGATORS  ................................ ................................ ................................ .... 56 
8.2 INSTITUTIONAL REVIEW BOARD REQUIREMENTS  ................................ ................................ ...........................  56 
8.3 INFORMED CONSENT  ................................ ................................ ................................ ................................ .. 56 
8.4 STUDY TRAINING  ................................ ................................ ................................ ................................ ........  57 
8.5 REQUIRED INVESTIGATIONAL EQUIPMENT  ................................ ................................ ................................ .... 57 
8.6   SITE ACTIVATION AND SUPPLY OF STUDY MATERIALS  ................................ ................................ ...................  58 
8.7 PROTOCOL AMENDMENTS  ................................ ................................ ................................ ..........................  58 
9.  CLINICAL STUDY PROCE DURES  ................................ ................................ ................................ ..................  59 
9.1 ELIGIBILITY CRITERIA  ................................ ................................ ................................ ................................ ... 62 
9.1.1  Inclusion Criteria for Thoracic Aortic Aneurysms and Penetrating Ulcers  ................................ .........  62 
9.1.2  Exclusion Cr iteria for Thoracic Aortic Aneurysms and Penetrating Ulcers  ................................ ........  63 
9.1.3  Inclusion Criteria for Chronic Type B Dissections  ................................ ................................ ..............  64 
9.1.4  Exclusion Criteria for Chronic Type B Dissections  ................................ ................................ .............  65 
9.2 PATIENT SCREENING , ENROLLMENT , AND PRE-IMPLANT PROCEDURES  ................................ ..........................  67 
9.3 STENT GRAFT IMPLANT PROCEDURES  ................................ ................................ ................................ ..........  69 
9.4 HOSPITAL DISCHARGE PROCEDURES  ................................ ................................ ................................ ...........  71 
9.5 REQUIRED FOLLOW -UP EVALUATIONS  ................................ ................................ ................................ ........  71 
9.6 UNSCHEDULED VISITS ................................ ................................ ................................ ................................  73 
9.7 PROTOCOL DEVIATIONS  ................................ ................................ ................................ .............................  73 
9.7. 1 Deviations with Expedited Reporting Requirements  ................................ ................................ .........  74 
9.7.2  Deviations Requiring Prior Approval  ................................ ................................ ................................ ... 74 
9.7.3  Non -Urgent Deviations  ................................ ................................ ................................ ......................  74 
9.8 TECHNICAL OBSERVATIONS  ................................ ................................ ................................ ........................  75 
9.9 ADVERSE EVENTS  ................................ ................................ ................................ ................................ ....... 75 
9.10  PATIE NT DEATH  ................................ ................................ ................................ ................................ .........  76 
9.11  EXPLANTED DEVICES  ................................ ................................ ................................ ................................ .. 77 
9.12  STUDY EXIT ................................ ................................ ................................ ................................ ................  78 
9.13  SUBJECT CONFIDENTIALITY  ................................ ................................ ................................ ........................  79 
9.14  DEVICE ACCOUNTABILITY  ................................ ................................ ................................ ...........................  79 
9.15  STUDY TERMINATION  ................................ ................................ ................................ ................................ .. 80 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 5 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 9.16  STUDY CLOSURE  ................................ ................................ ................................ ................................ ........  80 
10. ADVERSE EVENT DEFINI TIONS AND EXPEDITED REPORTING  ................................ ..............................  81 
10.1  DEFINITIONS  ................................ ................................ ................................ ................................ ..............  81 
10.2  EXPEDITED ADVERSE EVENT REPORTING  ................................ ................................ ................................ ..... 82 
11. DATA MANAGEMENT PROC EDURES  ................................ ................................ ................................ ...........  84 
11.1  CASE REPORT FORMS  ................................ ................................ ................................ ................................ . 84 
11.2  SOURCE DOCUMENTATION  ................................ ................................ ................................ .........................  84 
11.3  TRANSMISSION OF DATA ................................ ................................ ................................ .............................  85 
11.4  DATA QUERIES  ................................ ................................ ................................ ................................ ...........  85 
12. MONITORING AND AUDIT ING PROCEDURES  ................................ ................................ ............................  86 
12.1  CLINICAL STUDY SPONSOR AND MONITORS ................................ ................................ ................................ . 86 
12.2  MONITORING METHODS  ................................ ................................ ................................ .............................  86 
12.3  MONITORING VISITS ................................ ................................ ................................ ................................ ... 87 
13. RECORDS AND REPORTS  ................................ ................................ ................................ ..............................  88 
13.1  INVESTIGATOR RECORDS  ................................ ................................ ................................ ............................  88 
13.2  INVESTIGATOR REPORTS  ................................ ................................ ................................ .............................  88 
13.3 SPONSOR RECORDS  ................................ ................................ ................................ ................................ .... 90 
13.4  SPONSOR REPORTS  ................................ ................................ ................................ ................................ .... 90 
14. STUDY COMMITTEES  ................................ ................................ ................................ ................................ ..... 92 
14.1  CLINICAL EVENTS COMMITTEE  ................................ ................................ ................................ ....................  92 
14.2  DATA SAFETY MONITORING BOARD  ................................ ................................ ................................ ............  92 
14.3  INDEPENDENT PHYSICIAN REVIEWER  ................................ ................................ ................................ ............  93 
14.4  IMAGING CORE LAB ................................ ................................ ................................ ................................ ..... 93 
15. RISK ANALYSIS ................................ ................................ ................................ ................................ ................  94 
15.1  POTENTIAL RISKS ................................ ................................ ................................ ................................ ....... 94 
15.2  CLINICAL RISK BENEFIT  ................................ ................................ ................................ ...............................  97 
15.3  POTENTIAL BENEFITS  ................................ ................................ ................................ ................................ .. 97 
16. PUBLICATION POLICY  ................................ ................................ ................................ ................................ ... 99 
17. INSURANCE ................................ ................................ ................................ ................................ ....................  100 
18. OTHER RECORDS AND RE PORTS  ................................ ................................ ................................ ..............  101 
APPENDIX A – INSTRUC TIONS FOR USE  ................................ ................................ ................................ ............  103 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 6 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 APPENDIX B –DEFINITI ONS  ................................ ................................ ................................ ................................ .. 104 
APPENDIX C – ADVERSE  EVENT DEFINITIONS ................................ ................................ ................................ .. 108 
APPENDIX D – DEVICE -RELATED TECHNICAL OB SERVATIONS  ................................ ................................ ... 115 
APPENDIX E – INFORME D CONSENT TEMPLATE  ................................ ................................ ..............................  118 
APPENDIX F – LABELIN G ................................ ................................ ................................ ................................ ....... 119 
APPENDIX G – ASSESSM ENTS AND GUIDELINES  ................................ ................................ .............................  121 
AMERICAN SOCIETY OF ANESTHESIOLOGISTS (ASA)  PHYSICAL STATUS CLASSIFICATION SYSTEM ..............................  122 
MODIFIED SVS/AAVS  MEDICAL COMORB IDITY GRADING SYSTEM  ................................ ................................ ...........  123 
NIH  STROKE SCALE SCORIN G SYSTEM  ................................ ................................ ................................ ......................  124 
THE FOLSTEIN MINI-MENTAL STATUS EXAMINATION (MMSE)  ................................ ................................ ..................  125 
THE MODIFIED RANKIN SCALE (MRS) ................................ ................................ ................................ .......................  125 
CLASSIFICATION OF AORTIC ATHEROMA  ................................ ................................ ................................ ..................  126 
THORACIC DISSECTION MEASUREMENTS  ................................ ................................ ................................ .................  128 
IMAGING GUIDELINES  ................................ ................................ ................................ ................................ ..............  130 
APPENDIX H – EXPLANT  INSTRUCTIONS  ................................ ................................ ................................ ...........  134 
APPENDIX I - CMS STU DY CRITERIA  ................................ ................................ ................................ ...................  141 
APPENDIX J – TABLE O F CHANGES CIP VERSIO N 1A TO 1B  ................................ ................................ ...........  142 
APPENDIX K – TABLE O F CH ANGES CIP VERSION 1B  TO 1C  ................................ ................................ ...........  182 
APPENDIX L – TABLE O F CHANGES CIP VERSIO N 1C TO 1D ................................ ................................ ...........  183 
APPENDIX M – TABLE O F CHANGES CIP VERSIO N 1D TO 1E  ................................ ................................ ..........  194 
APPENDIX N – TABLE O F CHANGES CIP VERSIO N 1E TO 1F  ................................ ................................ ...........  195 
 
  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 7 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Clinical Study Synopsis  
Protocol Number:  10151194DOC  
Investigational 
Device:  Valiant Mona LSA Thoracic Stent Graft System  
(Comprised of the Main Stent Graft and Branch Stent Graft 
Systems)  
Study Title:  Evaluation of the Valiant Mona LSA Thoracic Stent Graft System 
in Descending Thoracic Aortic Aneurysms and Chronic 
Dissections  
Clinical Study Type:  Feasibility  
Sponsor:  Medtronic Vascular  
3576 Unocal Place  
Santa Rosa, CA 95403  
Indications for Use:  The Valiant Mona LSA Thoracic Stent Graft System is for the 
endovascular repair of fusiform/saccular aneurysms  , type B 
chronic dissections  (CTBD) , and penetrating ulcers  (PAU)  of the 
descending thoracic aorta (DTA) in patients who require 
coverage of the left subclavian artery (LSA) presenting with the 
appropriate  anatomy, including:  
Aortic diameter ≥ 5.5 cm or in whom the aneurysmal thoracic 
aorta is > 2 times the diameter of the non -aneurysmal thoracic 
aorta and which will require coverage of the LSA.  
Iliac or femoral artery access vessel morphology that is 
compa tible with vascular access techniques, devices, or 
accessories  
Non -diseased aortic diameter in the range of 25 mm to 42 mm 
for fusiform/saccular aneurysms and penetrating ulcers  
Non -diseased aortic diameter in the range of 28 mm to 44 mm 
for chronic disse ctions  
Non -diseased LSA diameter in the range of 8 mm to 13 mm  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 8 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Total effective  non -diseased aortic proximal neck length of > 0 
mm between the distal end of the LSA ostium to the beginning of 
the disease  
Total effective non -diseased aortic proximal neck len gth of ≥ 20 
mm between the distal end of left common carotid (LCC) ostium 
to the beginning of the disease, including ≥ 10 mm between the 
LSA and LCC  
Non -aneurysmal aortic distal neck length ≥ 20 mm  
Study Purpose:  The purpose of the clinical investigation  is to assess  the 
feasibility  of the Valiant Mona LSA Thoracic Stent Graft System  
to repair fusiform/saccular aneurysms, penetrating ulcers  and 
chronic type B dissections  of the DTA  in patients who require 
coverage  of the LSA , including an assessment of the safety and 
effectiveness of the device acutely and at the 30 day visit in the 
identified subject population. Procedural information  will be 
collected in order to enhance  the curre nt instructions for use and 
delivery and deployment steps.  
The chronic Type B Dissection expansion subjects will be 
prospectively enrolled in support of a future premarket approval 
analysis for the Valiant Mona LSA device.   
Product Status:  The Valiant Mona LSA Thoracic Stent Graft System is a modular 
system intended to maintain perfusion of the LSA when the 
device is implanted in Zone 2 of the aortic arch for the exclusion 
of a Thoracic Aortic Aneurysm (TAA), PAU, and CTBD.  
The Valiant Mona  LSA Thoracic Stent Graft System is comprised 
of two key components:  
• The Main Stent Graft (MSG) which is delivered using the 
Main Delivery System (MDS)  
• The Branch Stent Graft (BSG) which is delivered using the 
Branch Delivery System  (BDS)  
This device is c onsidered investigational in the United States 
(US).  
Study Objective:  The primary safety and effectiveness objectives will be measured 
acutely and at the 30 day visit after implantation of the Valiant 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 9 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Mona LSA Thoracic Stent Graft System. The safety parameters 
will be assessed through a composite at the 30 day visit post 
imp lantation, consisting of aorta -related mortality, stroke, 
paraplegia and left arm/hand ischemia.  
The primary effectiveness objective for the Valiant Mona LSA 
Thoracic Stent Graft System is defined as successful delivery and 
deployment of the Main Stent Gr aft (MSG) and Branch Stent 
Graft (BSG) at implant and successful exclusion of the 
aneurysm/penetrating ulcer or primary entry tear while 
maintaining patency of the BSG at the 30 day visit.  
In addition, analyses of periprocedural through discharge clinical  
utility measures will be conducted.  
Primary 
Observations:  Primary Safety Observation:  
Within 1 month (Day 0 – Day 30) from the index procedure, 
composite endpoint consisting of:  
• Aorta -Related Mortality  
• Stroke  
• Paraplegia   
• Left Arm/Hand Ischemia  
Primary Effectiveness Observation:  
The primary effectiveness observation is treatment success 
(defined below) and will be captured within the initial reporting 
period of 1 month from the index procedure. Treatment success  
is defined as technical success, which is the successful delivery 
and deployment of the stent graft (deployment of the Valiant 
Mona LSA Thoracic Stent Graft System in the planned location 
with no unintentional coverage of other vessels, assessed intra -
operatively, and the removal of the d elivery system) and 
successful exclusion of the aneurysm/penetrating ulcer or 
primary entry tear while maintaining patency of the MSG and BSG 
at the 30 day visit.  
Additional 
Observations:  Periprocedural through Discharge Clinical Utility Measures  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 10 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Mean duration (min) of procedure.  
•  Mean time (min) to implant the LSA Branch device.  
•  Proportion of subjects who underwent general 
anesthesia.  
•  Mean volume (cc) of estimated blood loss.  
•  Proportion of subjects requiring blood transfusions.  
•  Mean length of time (hours) in intensive care unit.  
•  Mean length of time (days) of overall hospital stay (from 
hospital admission to discharge).  
The following additional observations will be evaluated through 
30 days and at each follow -up visit:  
• Major adverse event (MAE) rate s within 30 days of the 
initial or secondary procedures, including:  
o  All-Cause Mortality  
o  Myocardial Infarction  
o  Paraplegia  
o  Renal Failure  
o  Stroke  
o  Left Arm/Hand Ischemia  
• Secondary endovascular procedures  
• Secondary endovascular procedures for primary device 
failures (including Type I/III endoleaks, aneurysm 
expansion, aneurysm/aortic rupture, and BSG occlusion  
• Rupture  
• Endoleaks  
• Maximum aneurysm diameter change from baseline*  
• Exclusion of aneurysm  
• Exclusion of penetrating aortic ulcer (PAU)  
• Stent graft patency  
• Stent graft integrity  
• Conversion to surgical repair  
• Surgical revascularization of the LSA  
• Paraparesis  
• Adverse events including serious adverse events and 
device, procedure, and/or disease -related adverse events  
• For CTBD, these additional observations will be evaluated:  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 11 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 o Coverage of primary entry tear (exclusion of false 
lumen)  
o Extension of dissection (proximally or distally) with 
or without complications  
o Continuing or new false lumen (FL) perfusion  
▪ Primary intimal tear false lumen perfusion 
(PIT FLP)  
▪ Proximal aorta false lumen perfusion (PA 
FLP)  
▪ Distal aorta false lumen perfusion (DA FLP)  
▪ Proximal branch false lumen perfusion (PB 
FLP)  
▪ Distal branch false lumen perfusion (DB FLP)  
o Aortic remodeling post -proced ure as measured by:  
▪ Change from baseline* in the maximum true 
lumen (TL) diameter over the length of the 
stent graft  
▪ Change from baseline* in the maximum false 
lumen (FL) diameter over the length of the 
stent graft  
▪ Change from baseline* in the maximum to tal 
descending  thoracic aortic diameter  
▪ FL thrombosis over the length of the stent 
graft  
* The discharge computerized tomography angiogram (CTA) will 
be used as baseline to assess aortic changes. If a discharge CTA 
is not performed, then the one month foll ow-up CTA will be used 
for baseline purposes.   
Study Design:  Prospective, single -arm, non -randomized, multicenter, pre -
market clinical study evaluating subjects implanted with the 
Valiant Mona LSA Thoracic Stent Graft System for the treatment 
of aneurysms/penetrating ulcers and chronic dissections of the 
descending thoracic aorta who are candidates for 
revascularization of the left subclavian artery .  
Patient Population:  Subjects diagnosed with an aneurysmal thoracic aorta, 
penetrating ulcer, or chronic Type B dissection who are 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 12 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 candidates for elective revascularization of the LSA and who 
meet the inclusion and exclusion criteria.  
Type of Control:  No control is expected f or this study. All subjects enrolled into 
this study will be followed for 5 years and information collected 
will be reported to the FDA on an annual basis, or as otherwise 
required by the agency.  
Number of 
Subjects:  44 subjects  
Following review of the preliminary safety data of the fir st 18 
enrolled patients, 5  additional subjects with TAA or PAU will be 
enrolled to further evaluate the device’s safety.  
The safety data for these 5 subjects will be reviewed by the 
investigator(s) in coordinati on with MDT  and the DSMB to 
determine whether to start enrollment of the CTBD arm . 
To ensure adequate disease state representation in the overall 
study dataset, a minimum of approximately 25% of the subjects 
will be enrolled for the treatment of TAA/PAU and a minimum  of 
approximately 25% of the subjects will be enrolled for the 
treatment of CTBD.   
Inclusion/Exclusion 
Criteria  
(Thoracic Aortic 
Aneurysms and 
Penetrating Ulcers , 
TAA/PAU ) Inclusion Criteria:  
• Subject is at least 18 years of age.  
• Subject understands and has signed an Informed Consent 
approved by the Sponsor and by the IRB for this  study . 
• Subject must be considered  a candidate for 
revascularization  of the LSA. Subject must be able to 
tolerate a surgical revascularization of the LSA.  
• Subject has a TAA/PAU which will require coverage  of the 
LSA and is:  
o a fusiform aneurysm with a diameter of ≥ 5.5 cm OR 
is > 2 times the diameter of the non -aneurysmal 
thoracic aorta;  
AND/OR  
o a saccular aneurysm or PAU (ulcer defined as ≥ 10 
mm in depth and 20 mm in diameter , or 
symptomatic)   
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 13 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Subject has a healthy, non -diseased aortic proximal seal 
zone of at leas t 20 mm from the distal end of the LCC 
ostium to the beginning of the disease, including at least 
10 mm between the LSA and the LCC.  
• Subject has a non -diseased aortic proximal neck length of 
>0mm distal to the LSA  
• Subject has a non -diseased aortic diamete r between 25 
mm and 42 mm  
• Subject has a non -diseased LSA with a diameter between 
8 mm and 13 mm.  
• Subject has sufficient landing zone within the LSA to 
accommodate the BSG without occlusion of any 
significant vessels  
• Brachial, i liac or femoral artery acces s vess el morphology 
(diameter, calcification , tortuosity) that is compatible with 
vascular access techniques, the device, or accessories.  
▪ Introducer sheath is required for all 
procedures.  
▪ An iliac conduit is required for access if the  
above  requirements a re not met.  
Exclusion Criteria  
• Subjects  will be excluded if they have conditions requiring 
prospective revascularization of the LSA including:  
o Dominant left vertebral artery requiring 
revascularization  
o Prior coronary artery bypass graft utilizing the left 
mammary artery requiring revascularization  
o Incomplete circle of Willis or other neurological 
vasculature requiring revascularization  
• Subject has an aneurysmal, tortuous, or atherosclerotic 
LSA.  
• Subject has an acute dissection of the descending 
thoracic aorta.  
• Subject has an intramural hematoma of the descending    
thoracic aorta.  
• Subject has prohibitive calcification, occlusive disease, or 
tortuosity of intended fixation sites.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 14 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Subject has circumferenti al calcification in the external 
iliac artery or in the common iliac artery with an 
intraluminal diameter (ID) less than 10mm at any point 
proximal to or at the access vessel site unless a surgical 
adjunctive procedure is planned.  
• Subject requiring an aort ic conduit or direct aortic access  
• Subject has an aortic atheroma classified as grade IV or 
grade V.  
• Subject has had previous endovascular repair of the 
ascending and/or descending thoracic aorta  <30 days of 
implantation of investigational device or previ ous repair 
was a non -Medtronic device . 
• Treatment with the Valiant Mona LSA Thoracic Stent 
Graft system would require intentional coverage of the 
left common carotid artery with the stent graft fabric.  
• Subject has significant and/or circumferential aortic m ural 
thrombus at either the proximal or distal attachment sites 
that would compromise fixation and seal of the device.  
• Subject is a pregnant female.  
• Subject has a known allergy or intolerance to the device 
components.  
• Subject is in acute renal failure or has renal insufficiency 
with a serum creatinine ≥ 2.0 mg/dL or is on dialysis.  
• Subject has a body habitus which prevents adequate 
visualization of the aorta.  
• Subject has coronary artery disease with unstable angina 
and who has not received treat ment.  
• Subject has a connective tissue disease (e.g. Marfan’s 
syndrome, medial degeneration).  
• Subject has active systemic infection and/or a mycotic 
aneurysm.  
• Subject is currently participating in an investigational drug 
or device clinical trial that would  interfere with the 
observations of this study.  
• Subject has other medical, social, or psychological 
problems that, in the opinion of the investigator, will 
interfere with treatment and follow -up procedures.  
• Subject has a life expectancy of less than 1 year . 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 15 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Subject requires treatment of an infrarenal aneurysm at 
the time of the implantation.  
• Subject has had previous surgical or endovascular 
treatment of an infra -renal aortic aneurysm  <30 days of 
implantation of investigational device . 
• Subject has a history of bleeding diathesis, coagulopathy, 
or refuses blood transfusion.  
• Subject has had a cerebral vascular accident (CVA) within 
3 months.  
• Subject has had a myocardial infarction (MI) within 3 
months.  
• Subject has a known hypersensitivity or contraindication 
to anticoagulants or contrast media, which is not 
amenable to pre -treatment.  
 
Inclusion/Exclusion 
Criteria  
(Chronic Type B 
Dissections , CTBD ) Inclusion Criteria  
• Subject is at least 18 years of age.  
• Subject understands and has signed an Informed Consent 
approved by the Sponsor and by the IRB for this study.  
• Subject must be considered a candidate for revascularization 
of the LSA. Subject must be able to tolerate a surgical 
revascularization of the LSA.  
• Subject has a CTBD which will require coverage  of the LSA. A  
CTBD is defined as > 30 days from symptom onset and is 
complicated with an aortic diameter ≥ 5.5  cm or has 
progressive aortic enlargement (> 5 mm/year).  
• Subject has a healthy, non -diseased aortic proximal seal zone 
of at least 20 mm from the  distal end of the LCC ostium to the 
beginning of the disease, including at least 10 mm between 
the LSA and the LCC as well as the diameter of the LSA 
ostium.  
• Subject has a non -diseased aortic diameter between 28 mm 
to 44 mm.  
• Subject has a non -diseased LS A with a diameter between 8 
mm and 13 mm.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 16 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Subject has sufficient landing zone within the LSA to 
accommodate the BSG without occlusion of any significant 
vessels  
• Brachial, iliac or femoral artery access vess el morphology 
(diameter, calcification , tortuosity ) that is compatible with 
vascular access techniques, the device, or accessories.  
▪ Introducer sheath is required for all 
procedures.  
▪ An iliac conduit is required for access if the  
above  requirements are not met.  
Exclusion Criteria  
• Subjects will be excluded if they have conditions requiring 
prospective revascularization of the LSA including:  
• Dominant left vertebral artery requiring revascularization  
• Prior coronary artery bypass graft utilizing the left 
mammary artery requiring revascularization  
• Incom plete circle of Willis or other neurological 
vasculature requiring revascularization  
• Subject has an aneurysmal, tortuous, or atherosclerotic LSA.  
• Subject has an acute dissection of the descending thoracic 
aorta.  
• Subject has an intramural hematoma of the de scending 
thoracic aorta.  
• Subject has prohibitive calcification, occlusive disease, or 
tortuosity of intended fixation sites.  
• Subject has circumferential calcification in the external iliac 
artery or in the common iliac artery with an intraluminal 
diameter (ID) less than 10mm at any point proximal to or at 
the access vessel site  unless a surgical adjunctive procedure 
is planned.  
• Subject requiring an aortic conduit or direct aortic access . 
• Subject has an aortic atheroma classified as grade IV or grade 
V. 
• Subject has had previous endovascular repair of the 
ascending and/or descending thoracic aorta  <30 days of 
implantation of inves tigational device or previous repair was a 
non -Medtronic device.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 17 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Treatment with the Valiant Mona LSA Thoracic Stent Graft 
system would require intentional coverage of the left 
common carotid artery with the stent graft fabric.  
• Subject has significant and/o r circumferential aortic mural 
thrombus at either the proximal or distal attachment sites 
that would compromise fixation and seal of the device.  
• Subject is a pregnant female.  
• Subject has a known allergy or intolerance to the device 
components.  
• Subject is in acute renal failure or has renal insufficiency with a 
serum creatinine ≥ 2.0 mg/dL or is on dialysis.  
• Subject has a body habitus which prevents adequate 
visualization of the aorta.  
• Subject has coronary artery disease with unstable angina and 
who has not received treatment.  
• Subject has a connective tissue disease (e.g. Marfan’s  
syndrome, medial degeneration).  
• Subject has active systemic infection and/or a mycotic 
aneurysm.  
• Subject is currently participating in an investigational drug or 
device  clinical trial that would interfere with the observations 
of this study.  
• Subject has other medical, social, or psychological problems 
that, in the opinion of the investigator, will interfere with 
treatment and follow -up procedures.  
• Subject has a life expe ctancy of less than 1 year.  
• Subject requires treatment of an infrarenal aneurysm at the 
time of the implantation.  
• Subject has had previous surgical or endovascular treatment 
of an infra -renal aortic aneurysm  <30 days of implantation of 
investigational devi ce. 
• Subject has a history of bleeding diathesis, coagulopathy, or 
refuses blood transfusion.  
• Subject has had a cerebral vascular accident (CVA) within 3 
months.  
• Subject has had a myocardial infarction (MI) within 3 months.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 18 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Subject has a known hypersensitiv ity or contraindication to 
anticoagulants or contrast media, which is not amenable to 
pre -treatment.  
Number of Sites:  Up to 10 investigational sites in the United States  
Sample Size 
Calculation:  There is no sample size calculation since this is not a hypothesis 
driven study; however, the number of enrolled subjects is pre -
specified. This study will enroll up to 44 subjects.   
Study Hypothesis:  N/A  
Analytical Sets:  All safety and effectiveness analyses will be performed on  all 
enrolled subjects , according to the intention -to-treat (ITT) 
principle.  The subject will be considered enrolled after arterial 
access is achieved and the Valiant Mona LSA Thoracic Stent 
Graft System has been introduced into the vasculature .        
The chronic Type B Dissecti on expansion subjects will be 
prospectively enrolled in support of a future premarket approval 
analysis for the Valiant Mona LSA device.   
Descriptive statistics will be used  for each subset  (TAA, PAU and 
CTBD) to analyze the primary observations, additiona l 
observations, and periprocedural and discharge clinical utility 
measures.  
Pre -Enrollment 
Testing:  Physical exams, vital signs, medical history, 3D CTA with 
visualization of geometry of aorta and branch vessel, CTA/MRA 
of head and neck vessels, Doppler Ultra Sound (DUS) of the 
LSA/carotid vessels, Neurological baseline exam  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 19 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Follow -Up 
Schedule:  Subjects will have required follow -up evaluations at these time 
points:  
1. Discharge  
2. 1 month post index procedure  
3. 6 months post index procedure  
4. 12 months post index procedure  
5. Annually thereafter, for a total of 5 years post index 
procedure  
Follow -Up Data 
Collection:  • Vital signs, Physical Exam, collection of Adverse Events at: 
1 month, 6 months, 12 months, 2, 3, 4 and 5 years.  
• CTA w/ 3D reconstruction at: discharge, 1 month, 6 
months, 12 months, 2, 3, 4 and 5 years.  
• Ultrasound of the LSA/thoracic branch vessels at: 
discharge, 1 month, 6 months, 12 months, 2, 3, 4 and 5 
years.  
• Chest X -Ray at: discharge, 1 month, 6 months, 12 months, 
2, 3, 4 and 5 years.  
• Additional imaging as required per physician  
Clinical Events 
Committee (CEC):  All MAEs as defined by the clinical investigational plan will be 
reviewed and adjudicated by the Clinical Events Committee 
(CEC). Any unanticipated adverse device events (UADEs) will be 
reviewed and adjudicated by the CEC. In addition, the CEC will 
review and adjudicate specific adverse events identified by the 
Sponsor or an independent Data Safety Monitoring Board 
(DSMB) that occur during the course of the t rial.  
 
Syntactx, LLC  
7 World Trade Center  
250 Greenwich Street  
46th Floor  
New York, NY 10007  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 20 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Data Safety 
Monitoring Board 
(DSMB):  Syntactx, LLC  
7 World Trade Center  
250 Greenwich Street  
46th Floor  
New York, NY 10007  
Independent 
Physician Reviewer  An Independent Physician Reviewer  will review imaging prior to 
subject enrollment into the study in order to determine that each 
subject meets the anatomical requirements set forth in this 
investigational plan .  
Principal 
Investigator:  Eric E. Ro selli, MD  
Cleveland Clinic  
9500 Euclid Avenue  
Cleveland, OH 44195  
Sponsor:   
 
 
Medtronic Vascular  
3576 Unocal Place  
Santa Rosa, CA 95403  
 
 
 
Safety Monitoring:  Medtronic Core Clinical Solutions  
710 Medtronic Parkway NE  
Minneapolis, MN 55432  
Monitoring:  Medtronic Clinical Operations  
710 Medtronic Parkway NE  
Minneapolis, MN 55432  
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 21 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 1. INTRODUCTION  
An Early Feasibility study was conducted in order to provide important information 
regarding the Valiant Mona LSA Thoracic Stent Graft System . This included:  
• Validat ion of  the procedure in humans, including the procedural steps, physician 
technique, and patient characteristics.  
• Assess ment of the safety and performance of the device acutely and at the 30 day  
visit , specifically in regards to delivery and deployment and exclusion of the 
aneurysm and patency of the LSA.  
• Collection of thoracic arch movement parameters in humans, both before  and after 
placement of the device.  
• Collect ion of  imaging data to augment the current use conditions data set.  
The device was successfully implanted into nine (9) subjects and continues to function as 
intended. Data collected from the Early Feasibility s tudy allowed Medtronic to identify 
implantation procedural steps that required further clarification, in particular that 
manipulations of the stent graft devices and accessory devices should be performed distal 
to the LSA. In order to fu rther  characterize the study device , ad ditional s ubjects will be 
enrolled into a Feasibility study for the Valiant Mona LSA Thoracic Stent Graft System.  
The purpose of the Feasibility Study i s to characterize the Valiant Mona LSA Thoracic 
Stent Graft System, in particular to assess the safety and effectiveness  of the device 
acutely and at the 30 day  visit  in the identified subject population . This study will also 
evaluate the current instructions for use (IFU) and may  direct changes to the delivery and 
deployment steps .  
The purpose of the expansion to the Feasibility Study i s to characterize the Valiant Mona 
LSA Thoracic Stent Graft System, in particular to assess the safety and effectiveness of 
the device acutely and at the 30 day visit, in subjects enrolled with chronic, Type B 
dissections. The chronic Type B  Dissection  exp ansion subjects will be prospectively 
enrolled in support of a future premarket approval analysis for the Valiant Mona LSA 
device . This Clinical Investigational P lan (CIP) describes the study requirements for the 
Valiant Mona LSA Thoracic Stent Graft Syste m.  
As the Sponsor of this clinical study, Medtronic Vascular  has the overall responsibility for 
the conduct of the study, including assurance that the study will be performed  according 
to the Investigational Plan and the US Food and Drug Administration (FDA) regulations.  
During this study, Medtronic Vascular will have certain direct responsibilities and may 
delegate other responsibilities to, for example, a Physician Screening Committee, and/or 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 22 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 CRO s. Medtronic Vascular and/or its designees  will conform to the US Code of Federal 
Regulations (CFR) including:  Investigational Device Exemptions (21 CFR 812), Electronic 
Records/Electronic Signatures (21 CFR 11), Protection of Human Subjects (21 CFR Part 
50), Financial Disclosure by Clinical Inves tigators (21 CFR Part 54), and Institutional Review 
Boards (21 CFR 56).  
  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 23 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 2. BACKGROUND  
There has been a remarkable evolution in the treatment of thoracic aortic disease s, from 
open surgery to endovascular therapy, which has significantly decreased morbidity and 
mortality in these patients.1  
The early success of endovascular stent graft repair of abdominal aortic aneurysms (AAA) 
has fostered the application of these devices for the management of descending thoracic 
aortic diseases, including thoraci c aortic aneurysms (TAA), acute and chronic Type B 
dissection, intramural hematoma, penetrating ulcer, traumatic injury, mycotic aneurysms 
                                                 
1 Narayan P, Wong A, Davies I, Anegelini GD, Bryan AJ, Wilde P, Murphy GJ.  Thoracic endovascular repair 
versus open surgical repair – which is the more cost -effective intervention for descending thoracic aortic 
pathologie s? Eur J Cardiothorac Surg. 2011:40(4):869 -74.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 24 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 and anastomotic aneurysms.2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17 This procedure offers an 
alternative method of treatment th at is potentially less invasive, less expensive, and less 
risky than standard operative repair.18 Endovascular repair of thoracic aortic pathology 
consists of trans -femoral or iliac introduction of a metallic stent coupled with a vascular 
graft.  When the st ent graft device is deployed and expanded within the diseased blood 
vessel, the stent graft  creates a new aortic lumen for blood flow, excluding the lesion from 
blood flow while maintaining perfusion to the lower body . Essential design features of 
                                                 
2 Doroghazi RM, Slater EE, DeSanctis RW, Buckley MJ, Austen WG, Rosenthal S. Long -term survival of 
patients with treated aortic dissection. J Am Coll Cardiol. 1984;3:1026 -1034.  
3 Appelbaum A, Karp RB, Kirklin JW. Ascending vs descending aortic dissections. Ann Surg. 1976;183:296 -
300.  
4 Jex RK, Schaff HV, Piehler JM, King RM, Orszulak TA, Danielson GK, Pairolero PC, Pluth JR, Ilstrup D. Early 
and late results following repair of dissections of the descending tho racic aorta. J Vasc Surg. 1986;3:226 -
237.  
5 Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic  
aneurysms. Ann Vasc Surg 1991;5:491 -9. 
6 Kato N, Hirano T, Shimono T et al. Treatment of chronic type B aortic dissection with endovascular stent -
graft placement. Cardio -vasc Interv Radiol 2000;23:60 -2. 
7 Yusuf SW, Baker DM, Chuter TA et al. Transfemoral endoluminal repair of abdominal aortic aneurysm with 
bifurcated graft. Lancet  1994;344:650 -1. 
8 Moore WS, Vescera CL. Repair of abdominal aortic aneurysm by transfemoral endovascular graft placement. 
Ann Surg 1994;220:331 -41. 
9 Blum U, Langer M, Spillner G et al. Abdominal aortic aneurysms: preliminary technical and clinical result s 
with transfemoral placement of endovascul ar self -expanding stent -grafts. Radiology 1996;198:25 -31. 
10 Mitchell RS, Dake MD, Semba CP et al. Endovascular stent -graft repair of thoracic aortic aneurysms. J 
Thorac Cardiovasc Surg 1996;111:1054 -62.  
11 Dake MD, miller DC, Mitchell RS et al. The “first generation” of endovascular stent -grafts for patients with 
aneurysms of the descending thoracic aorta. J Thorac Cardiovasc Surg 1998;116:689 -703.  
12 Kato N, Dake MD, Miller DC et al. Traumatic thoracic aortic aneurysm: treatment with endovascular stent -
grafts. Radiology 1997;205:657 -62.  
13 Semba CP, Sakai T, Slonim S M et al. Mycotic aneurysms of the thoracic aorta: repair with use of 
endovascular stent -grafts. J Vasc Interv Radiol 1998;9:33 -40.  
14 Sakai T, Dake MD, Semba CP et al. Descending thoracic aortic aneurysm: thoracic CT findings after 
endovascular stent -graft placement. Radiology 1999;212:169 -74.  
15 Nienaber CA, Fattori R, Lund G et al. Nonsurgical reconstruction of thoracic aortic dissection by stent -graft 
placement. N Engl J Med 1999;340:1539 -45.  
16 Dake MD, Miller DC, Semba CP et al. Transluminal placement of endovascular stent -grafts for the 
treatment of descending thoracic aortic aneurysms. N Engl Med 1994;331:1729 -34.  
  17 Criado FJ, Clark NS, BArnatan MF. Stent graft repair in the aortic arch and descending thoracic aorta: a 4 
year experience. J Vasc Surg 2002; 36 (6): 1121 -8. 
18 Semba CP, Dake MD. Endoluminal Stent -Grafting in the Thoracic Aorta. In Chuter TAM, Donayre CE, White 
RA (eds). Endoluminal Vascular Prostheses. Boston: Little, Brown and C ompany; 1995:153 -171.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 25 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 conventi onal surgical vascular grafts, such as low blood permeability, resistance to radial 
dilatation, and long -term patency, are also important for a covered endoluminal stent 
graft.  In addition, stent grafts must firmly anchor to the artery wall, without the use of 
sutures.  The following sections discuss treatment of descending thoracic aortic aneurysm 
and dissection in greater  detail.  
Descending Thoracic Aortic Aneurysm  
An aortic aneurysm is defined as a dilatation of the aortic vessel greater than 50% of it s 
normal diameter for a given segment of the adhering normal vessel.19 A descending 
thoracic aneurysm (DTA) is defined as involving any portion of the thoracic aorta distal to 
the left subclavian artery and extending to above the diaphragm.20 In adults, the diameter 
of the normal aorta is approximately 30 mm at the aortic root and approximately 25 mm at 
the level of the diaphragm. Age is the major influential factor in aortic diameter 
enlargement and all aortic diameters increase with age.21 It has been report ed that aortic 
diameters increase about 1 mm per decade during adulthood.22 Generally, a diameter in 
the thoracic aorta greater than 4.5 cm is considered aneurysmal.19,20,21,22,23 
A DTA is a life -threatening condition. Annually, the incidence of thoracic aor tic aneurysms 
(TAA) in a population -based study is 10.4 per 100,000 person -years, and the descending 
thoracic aorta is involved in about 40% of those cases.24 The number of people diagnosed 
with DTA is thought to be increasing. Factors that contribute to th is rise include increased 
                                                 
19 Faries PL, Dayal R, Lin S, Trociolla S, Rhee J, Craig Kent K. Endovascular stent graft selection for the 
treatment of abdominal aortic aneurysms. J Cardiovasc Surg 2005;46:9 -17.  
20 Zarins CK, White RA, Schwarten D, et al. AneuRx ste nt graft versus open surgical repair of abdominal aortic 
aneurysms: multicenter prospective clinical trial. J Vasc Surg 1999;29:292 -308.   
21 Brewster DC, Geller SC, Kaufman JA, et al. Initial experience with endovascular aneurysm repair: 
comparison of early  results with outcome of conventional open repair. J Vasc Surg 1998;27:992 -1005.   
22 Matsumura JS, Brewster DC, Makaroun MS, Naftel DC. A multicenter controlled clinical trial of open versus 
endovascular treatment of abdominal aortic aneurysm. J Vasc Surg 2 003;37:262 -271.  
23 Salartash K, Sternbergh III WC, York JW, Money SR. A comparison of open transabdominal AAA repair with 
endovascular AAA repair in reduction of postoperative stress response. Ann Vasc Surg 2001;15:53 -59.  
24 Cuypers WM, Gardien M, Buth J, et al. Randomized study comparing cardiac response in endovascular and 
open abdominal aortic aneurysm repair. Br J Surg 2001;88:1059 -1065.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 26 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 longevity of the population and improved diagnostic capability.24,25,26 The natural history of 
TAA, including DTA, is one of progressive enlargement and rupture, and rupture is almost 
invariably fatal. Current available treatment op tions include medical treatment, open 
surgical repair, and endovascular stent graft repair.  
Standard surgical treatment involves a thoracotomy, aortic clamping, re -section of the 
aneurysmal segment, and replacement using a Dacron graft. Thoracic endovascu lar aortic 
repair (TEVAR) consists of transfemoral or iliac introduction of the device. When the stent 
graft device is deployed and expanded within the aneurysmal blood vessel, it creates a new 
aortic lumen for blood flow, excluding the aneurysm sac, while  maintaining perfusion to the 
lower body. Studies comparing open surgical repair to endovascular repair concluded that 
the latter offers a less invasive, less expensive alternative, a decrease in mortality and 
morbidity in high -risk patients, and is associ ated with a shorter hospital stay and a quicker 
return to normal activities after surgery.27,28 Because of the invasive nature of the open 
surgical repair, physicians consider multiple endovascular options for high -risk patients. 
Dissection  
Improved diagnost ic imaging modalities combined with longer life expectancy and 
exposure to high blood pressure has enhanced awareness of the spectrum of acute and 
chronic aortic syndromes.29 One such condition is aortic dissection, which involves a 
progressive tear in the aorta. The inner lining (intima) of the aorta tears resulting in 
propagation of blood within the middle layer (media), usually distally, but sometimes 
retrograde with multiple reentry sites. An aortic dissection is classified as Stanford Type A 
or B depend ing on involvement of the ascending or descending thoracic aorta . Type A 
dissection begins in the ascending part of  the aorta and typically moves to another part of 
the chest.  Type B dissection begins in the descending part of the  aorta and typically moves  
                                                 
25 EVAR trial participants. Endovascular aneurysm repair versus open repair in patients  with abdominal aortic 
aneurysm (EVAR trial 1): randomized controlled trial. Lancet 2005;365:2179 -2186.  
26 Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison of endovascular aneurysm repair with open repair 
in patients with abdominal aortic aneurysm (EVAR  trial 1), 30 -day operative mortality results: randomized 
controlled trial. Lancet. 2004;364:843 -848.  
27 Sicard GA, Zwolak RM, Sidawy AN, White RA, Siami FS. Endovascular abdominal aortic aneurysm repair: 
long -term outcome measures in patients at high risk for open surgery. J Vasc Surg 2006;44:229 -236.   
28 Du Toit DF, Saaiman JA, Carpenter JP, Geldenhuys KM. Endovascular aortic aneurysm repair by a 
multidisciplinary team: lessons learned and six -year clinical update. Cardiovasc J South Africa           
29 Nienaber CA, Eagle KA.  Aortic dissection: new frontiers in diagnos is and management: Part I: from etiology 
to diagnostic strategies. Circulation. 2003 Aug 5;108(5):628 -35.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 27 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 towards the abdomen, but in certain circumstances can also propagate towards the 
heart.30 
Conventional treatment of thoracic aortic dissection has either been medical management 
or an open surgical procedure, depending upon the patient’s clinical presentat ion. For 
Type B aortic dissections a complication specific treatment approach with surgery is 
usually followed with medical management applied as the primary treatment for 
uncomplicated cases. Medical management primarily focuses on reducing blood pressure 
to reduce the stresses on the diseased vessel, but does not treat the dissection or 
underlying disease.  This has been the preferred treatment for acute Type B dissections in 
many institutions.2,3,4,31,32,33,34,35 Outcomes prior to hospital discharge fo r uncomplicated, 
acute Type B dissections are considered acceptable with 90% survival reported;36 
however, 20% to 40% of patients who have passed their acute phase with medical anti -
hypertensive therapy will likely need surgery during the chronic phase due to aneurysmal 
enlargement of the aortic dissection.2,31,32,35,37  
Complicated dissection is associated with at least one of the following:  malperfusion 
syndrome (visceral, renal or lower limb), rupture, uncontrollable hypertension or refractory 
pain. Patien ts with acute, complicated Type B aortic dissections are reported to have a 
greater than 50%38 likelihood of dying from this disease and as such require emergent 
surgical treatment.  
                                                 
30 Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE: Management of acute aortic dissections. 
Ann Thorac Surg 1970;10:237 -247.  
31 Anagnostopo ulos CE, Prabhakar MJS, Kittle CF. Aortic dissections and dissecting aneurysms. Am J Cardiol. 
1972;30:263 -273.  
32 Wheat MW Jr. Current status of medical therapy of acute dissecting aneurysms of the aorta. World J Surg. 
1980;4:563 -569.  
33 Wheat MW Jr. Acute dissection of the aorta. Cardiovasc Clin. 1987;17:241 -262.  
34 Kirkorian G, Hochmann B, Kassis A, Atallah G, Mathieu MP, Rossi R, Sagnol P, Touboul P. Long -term 
prognosis of patients with acute type B aortic dissection treated medically. J Am Coll Cardiol. 1988;11:162A.  
35Glower DD, Fann JI, Speier RH, Morrison L, White WD, Smith LR, Rankin JS, Miller DC, Wolfe WG. Comparison 
of medical and surgical therapy for uncomplicated descending aortic dissection. Circulation. 1990;82(suppl 
IV):IV -39-IV-46.  
36Hagan PG, Nienaber CA, Isselbacher Em et al. The International Registry of Acute Aortic Dissection (IRAD): 
New Insights Into an Old Disease. JAMA. 2000; 283:897 -903.  
37 Neya K, Omoto R, Kyo S, Kimura S, Yokote Y, Takamoto S, Adachi H. Outcome of Stanford Type B acute 
aortic dissection. Circulation. 1992;86(suppl II):II -1-II-7. 
38 Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Bossone E, Tolva V, Deeb MG, Upchurch GR Jr, 
Cooper JV, Fang J, Isselbacher EM, Sundt TM 3rd, EagleKA; IRAD Investi gators. Role and results of surgery in 
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 28 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Open surgical repair of type B aortic dissection has been reserved for pat ients presenting 
with complications such as imminent rupture, expansion of the aorta, extension of 
dissection, organ or limb malperfusion syndromes.39,40 Standard surgical technique 
requires resection of the severely damaged segments of the aorta and replace ment with a 
Dacron graft. This procedure involves a thoracotomy, significant blood loss, aortic 
clamping, and possibly aortic bypass.  The surgical mortality rate has been reported to be 
as high as 35% and even higher (50%) in patients with acute disease an d end organ 
ischemia or rupture.38,39,40 Neinaber29 reported a 20% mortality rate by day 2 and 25% by 
day 30 for patients with type B dissections who have ischemic leg symptoms, renal failure, 
visceral ischemia or contained rupture. Suzuki et al41 reported a 32% in hospital mortality 
rate for acute, complic ated type B dissection patients who required surgery. Trimarchi et 
al38 reported a 29.3 % hospital mortality rate for patients who required surgical treatment 
of acute, complicated Type B dissections. Fann et al42 reported a 39 + 8% hospital 
mortality rate f or acute, complicated Type B dissection patients. Open thoracic surgeries 
are ranked among the most complex, invasive and extensive surgical procedures.   
Chronic type B dissection is defined as an aortic dissection that is treated greater than 30 
days after symptom onset. The natural history for chronic type B dissection is different 
based on which part of the thoracic aorta is involved, the ascending aorta or the 
descending aorta. Having a history of Marfan’s syndrome, age, greater size of aorta at 
bas eline, persistent hypertension that is not well controlled, and having a patent false 
lumen are risk factors that predispose these patients to development of aorta -related 
complications during the chronic phase.  Aortic growth rate may be from 10mm to  74mm 
                                                 
acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection 
(IRAD).Circulation. 2006 Jul 4;114(1 Suppl):I357 -64. 
39 Song TK, Donayre CE, Walot I, Kopchok GE, Litwinski RA, Lippma nn M, SarkisyanGE, Omari B, White RA. 
Endograft exclusion of acute and chronic descending thoracic aortic dissections. J Vasc Surg. 2006 
Feb;43(2):247 -58.  
40 Dake MD, Kato N, Mitchell RS et al. Endovascular stent -graft placement for the treatment of acute a ortic 
dissection. N Engl J Med 1999;340:1546 -52.  
41 Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, Sumiyoshi T, Bossone E, Trimarchi S, Cooper 
JV, Smith DE, Isselbacher EM, Eagle KA, Nienaber CA; International Registry of Aortic Dissection. Clini cal 
profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International 
Registry of Aortic Dissection (IRAD). Circulation. 2003 Sep 9;108 Suppl 1:II312 -7. 
42 Fann JI, Smith JA, Miller DC, Mitchell RS, Moore KA, Grunkem eier G, Stinson EB, Oyer PE, Reitz BA, 
Shumway NE. Surgical management of aortic dissection during a 30 -year period. Circulation. 1995 Nov 
1;92(9 Suppl):II113 -21.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 29 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 per year,43 dependent on if the false lumen is patent, if hypertension is controlled, and what 
the baseline aortic diameter was at diagnosis. The most common causes of morbidity and 
mortality for patients with chronic type B dissection are aortic rupture, a neurysmal 
degeneration of the aorta, and malperfusion leading to ischemia.43  
Treatment of type B aortic dissections includes optimal medical therapy (OMT) for those 
patients who are stable, open surgical repair for those patients who are symptomatic and 
have lower surgical risks based on their medical history and presentation, and 
endovascular repair for symptomatic patients at higher risk for open surgery. 
Hypertensive and beta -blocker medications are considered foundations of OMT for 
patients who make th e transition from acute to chronic aortic dissection.44 OMT plays an 
important role in patients who have chronic distal aortic dissection, yet some patients’ 
aortas continue to enlarge and become aneurysmal.45,46,47,48 A high incidence of 
enlargement, with women having a higher risk of enlargement, during the follow -up period 
has been reported, with a growth rate in the thoracic aorta as great as 4 mm/year.49 One -
third of patients with OMT for uncomplicated acute type B aortic dissection will require 
surgery for aortic -related complications within 5 years of their dissection event, most 
often for aneurysmal enlargement of the chronic thoracic aortic dissection.50 Once the 
aortic diameter exceeds 55 to 60 mm, the risk of ao rtic rupture is estimated at 30% per 
year.51 Other sequelae, such as the onset of unrelievable pain or progression of the initial 
dissection including organ malperfusion may necessitate urgent or emergent repair of the 
                                                 
43 Giugliano G, Spadera L, De Laurentis M, Brevetti G. Acta Cardiol. 2009 Oct;64(5):653 -663.  
44 Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic beta -blocker therapy improves outcome 
and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg 2001;19:606 –10.  
45 Halstead JC, Meier M, E tz C, et al. The fate of the distal aorta after repair of acute type A aortic dissection. J 
Thorac Cardiovasc Surg 2007;133:127 –35. 
46 Haverich A, Miller DC, Scott WC, et al. Acute and chronic aortic dissections –determinants of long -term 
outcome for operati ve survivors. Circulation 1985;72 (3 pt 2):II22 –34.  
47 Masuda Y, Yamada Z, Morooka N, Watanabe S, Inagaki Y. Prognosis of patients with medically treated 
aortic dissections. Circulation 1991;84(5 suppl):III7 –13.  
48 Glower DD, Fann JI, Speier RH, et al. Compa rison of medical and surgical therapy for uncomplicated 
descending aortic dissection. Circulation 1990;82(5 suppl):IV39 –46.  
49 Sueyoshi E, Sakamoto I, Hayashi K, Yamaguchi T, Imada T. Growth rate of aortic diameter in patients with 
type B aortic dissection during the chronic phase. Circulation 2004;110(11suppl 1):II256 –61.  
50 Hughes GC, Ganapathi AM, Keenan JE, Englum BR, Hanna JM, Schechter MA, Wang H, McCann RL. 
Thoracic endovascular aortic repair for chronic DeBakey IIIb aortic dissection. Ann Thorac Surg 2014;  Dec 
98(6):2092 -2097.  
51 Fattori R, Cao P, De Rango P, et al. Interdisciplinary expert consensus document on management of type B 
aortic dissection. J Am Coll Cardiol 2013;61:1661 –78.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 30 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 chronic thoracic aortic dissection.52,53,54 Surgical options for these patients include open 
surgical repair (OSR) or thoracic endovascular aortic repair (TEVAR).  
Pertaining to OSR for the treatment of patients with chronic type B aortic dissections, the 
early mortality rate from literature with  contemporary data with available endograft 
technology was 8.0%, with rate of other complications such as early stroke and spinal cord 
ischemia at 5.5% and 5.7%, respectively.51 These rates indicate that surgical repair of 
chronic dissection is usually fol lowed by a non -negligible rate of short -term morbidity and 
mortality. In the longer -term, patients who are treated by OSR have mortality rates that 
are in line with TEVAR.55,56 Reintervention after OSR is uncommon and the false lumen is at 
a lower risk of ru pture due to the aortic resection as shown in a propensity adjusted 
analysis of OSR and TEVAR as reported by treatment efficacy 3 -year freedom rupture or 
reintervention at rates of 96.7% for OSR vs TEVAR at 87.5%.56 More detail pertaining to 
complication r ates associated with TEVAR are reported in the sections below.  
TEVAR has a documented lower rate of perioperative mortality, shorter hospital stays, and 
post -operative morbidity and mortality in comparison to open surgical repair for patients 
treated for c hronic type B dissection.57 In addition, TEVAR is associated with improved 
long -term aortic mortality and slowing of disease progression.58 However, patients 
treated with TEVAR for chronic type B dissection have a higher rate of post -operative 
                                                 
52 Hata M, Shiono M, Inoue T, et al. Optimal treatment of type B acute aortic dissection: long -term medical 
follow -up results. Ann Thorac Surg 2003;75:1781 – 4. 
53 Gysi J, Schaffner T, Mohacsi P, Aeschbacher B, Althaus U, Carrel T. Early and late outcome of ope rated and 
nonoperated acute dissection of the descending aorta. Eur J Cardiothorac Surg 1997;11:1163 –70. 
54 Zoli S, Etx CS, Roder F, Mueller CS, Brenner RM, Bodian CA, Di Luozzo G, Griepp RB. Long -term survival 
after open repair of chronic distal aortic dis section. Ann Thorac Surg 2010;89:1458 -1466.   
55 Anderson ND, Keenan JE, Ganapathi AM, Gaca JG, McCann RL, Hughes GC. Current management and 
outcome of chronic type B aortic dissection: results with open and endovascular repair since the advent of 
thoracic endografting. Ann Cardiothorac Surg. 2014;3(3):264 -274.  
56 Van Bogerijen GHW, Patel HJ, Williams DM, Yang B, Dasika NL, Eliason JL, Deeb GM. Propensity adjusted 
analysis of open and endovascular thoracic aortic repair for chronic type B dissection:  a twenty -year 
evaluation. Ann Thorac Surg. 2015;99:1260 –6. 
57 Chou HP, Chang HT, Chen CK, Shih CC, Sung SH, Chen TJ, Chen IM, Lee MH, Sheu MH, Wu MH, Chang CY. 
Outcome comparison between thoracic endovascular and open repair for type B aortic dissection: a 
population based longitudinal study. J Chin Med Assoc. 2015 Apr;78(4):241 -248.  
58 Nienaber CA, Kische S, Rousseau, H, Eggebrecht H, Rehders TC, Kundt G, Glass A, Scheiner D, Czerny M, 
Kleinfeldt T, Zipfel B, Labrousse L, Fattori R, Ince H. Lon g-term results of the randomized investigation of the 
stent grafts in aortic dissection trial. Circ Cardiovasc Interv. 2013 Aug;6(4):407 -416.  
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 31 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 secondary inte rventions for aortic dissection pathology than in open repair,59 with rates 
for aortic dissection as high as 38 -72% at 3 years60,61,62 and as high as 13 -41% for chronic 
type B dissection.63,64 The lack of TEVAR durability in treatment of aortic dissection may be  
attributable to the fragility of the aortic tissues involved in the repair. The necessity for 
secondary interventions to address continued false lumen perfusion and aneurysm 
expansion post -TEVAR for aortic dissection may be an expected part of the treatme nt 
standard for these patients, yet these secondary interventions are not impacting long -
term survival for these patients.65  
Penetrating Atherosclerotic Ulcer  
Penetrating atherosclerotic ulcer (PAU) occurs most often in patients with extensive 
atherosclero tic disease. PAU is defined by an ulceration of an aortic atherosclerotic plaque 
penetrating through the internal elastic lamina into the aortic media. PAUs can progress to 
a localized aneurysm, IMH, or free wall rupture.66 PAU is associated with a n elderly  patient 
population having a history of moderate to severe hypertension, tobacco use, and a 
heavily lined atherosclero tic aorta. The patients typically are symptomatic on 
                                                 
59 Nozdrzykowski M, Etz CD, Luehr M, Garbade J, Misfeld M, Borger MA, Mohr FW. Optimal treatment for 
patients with chronic Stanford type B aortic dissection: endovascularly, surgically or both? Eur J 
Cardiothorac Surg. 2013 Sep:44(3):e165 -174.  
60 Eggebrecht H, Nienaber CA, Neuhauser M, Baumgart D, Kische S, Schmermund A, et al. Endovascular 
stent -graft placement in aort ic dissection: A meta -analysis. Eur Heart J. 2006; 27:489 –498.  
61 Schoder M, Czerny M, Cejna M, Rand T, Stadler A, Sodeck GH, et al. Endovascular repair of acute type b 
aortic dissection: Long -term follow -up of true and false lumen diameter changes. Ann Tho rac Surg. 2007; 
83:1059 –1066.  
62 Sayer D, Bratby M, Brooks M, Loftus I, Morgan R, Thompson M. Aortic morphology following endovascular 
repair of acute and chronic type b aortic dissection: Implications for management. Eur J Vasc Endovasc Surg. 
2008; 36:522 –529.  
63 Parsa CJ, Schroder JN, Daneshmand MA, McCann RL, Hughes GC. Midterm results for endovascular repair 
of complicated acute and chronic type b aortic dissection. Ann Thorac Surg. 2010; 89:97 –102. discussion 
102 -104.  
64 Kang WC, Greenberg RK, Mastracci T M, Eagleton MJ, Hernandez AV, Pujara AC, et al. Endovascular repair 
of complicated chronic distal aortic dissections: Intermediate outcomes and complications. J Thorac 
Cardiovasc Surg. 2011; 142:1074 –1083.  
65 Scali ST, Beck AW, Butler K, Feezor RJ, Martin T D, Hess PJ, Huber TS, Chang CK. Pathology -specific 
secondary aortic interventions after thoracic endovascular aortic repair. J Vasc Surg. 2014 Mar;59(3):599 -
607.  
66 Brinster DR. Endovascular repair of the descending thoracic for penetrating atherosclerotic ulcer disease. J 
Cardiovasc Surg. 2009;24:203 -8. 
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 32 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 presentation.67,68 Aggressive management is recommended for PAUs as there is a higher 
rate of rupture (as high as 38%) associated with this pathology acutely , yet asymptomatic 
PAUs have lower rates of rupture and disease progression .69 Figure 2-1 below shows the 
management pathway for PAU. As shown, TEVAR is the preferred treatment course in 
both acute and chronic settings, unless contraindicated.70  
                                                 
67 Cho KR, Stanson AW, Potter DD, Cherry KJ, Schaff HV, Sundt TM. Penetrating atherosclerotic ulcer of the 
descending thoracic aorta and arch. J Thorac Cardiovasc Surg. 2004;127:1393 -1401.  
68 Coady MA, Rizzo J A, Hammond GL, Pierce JG, Kopf GS, Elefteriades JA. Penetrating ulcer of the thoracic 
aorta. What is it? How do we recognize it? How do we manage it? J Vasc Surg. 1998;27:1006 –16.  
69 Nathan DP, Boonn W, Lai E, et al. Presentation, complications and natura l history of penetrating 
atherosclerotic ulcer disease. J Vasc Surg. 2012;55:10 –5. 
70 Evangelista A, Czerny M, Nienaber C, Schepens M, Rousseau H, Cao P, Moral S, Fattori R. Interdisciplinary 
expert consensus on management of type B intramural hematoma and  penetrating aortic ulcer. Eur J 
Cardiothorac Surg. 2015;47(2):209 -217.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 33 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
Figure 2-1: Acute and Chronic Management Pathway for PAU70 
Open surgical repair in an elderly population with comorbidities such as coronary artery 
disease and chronic obstructive pulmonary disease, carries a high risk of mortality (15%) 
for patients with PAUs.67 TEVAR is an acceptable alternative to open surgical repair for 
PAU, having a lower acute mortality rate than open surgery (7.2% vs 15.9%, respectively) 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 34 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 and a reported CVA rate of 4%.71 Secondary interventions relate d to endoleaks or other 
post -operative aorta -related changes may occur in patients treated for PAU. One article71 
cites a rate as high as 21% of secondary interventions for PAU patients.  
While endovascular stent graft treatment has significantly improved outcomes in patients 
with DTA  disease, further evolution and innovation of these devices is necessary  as many 
patients have disease that involves the aortic arch . The stent grafts currently available in 
the United States for treatment of disease of the DTA  require a minimum proximal neck 
length (the distance from the proximal edge of the aneurysm to the distal origin of the LSA) 
in order to ensure an adequate seal of the graft to healthy aorta. Approximately 40% of 
TEVAR patients do not meet this criteria.72,73 In these cases, consideration needs to be 
given to whether the patient’s left subclavian artery (LSA) provides additional treatment 
options, whereby covering the origin of the LSA with the fabric portion of a stent graft 
lengthens the proximal landing z one. When blood flow is excluded from the LSA, patients 
are at a higher risk of left arm ischemia, spinal cord ischemia, vertebrobasilar ischemia, 
anterior circulation stroke, and death.74  
To manage the treatment of these patients, consideration is given w hether or not to 
revascularize the LSA. Revascularization can be performed before TEVAR or after, if 
symptoms present. The Society for Vascular Surgery’s (SVS) published practice guidelines 
recommend preoperative revascularization in all patients unless an  emergent situation 
prevents the option or local surgical expertise is unavailable.75 Patients for which 
preoperative revascularization is strongly recommended include those with:  
• Coronary artery bypass graft involving a patent left internal mammary artery  
                                                 
71 Czerny M, Funovics M, Sodeck G, Dumfarth J, Schoder M, Juraszek A, Dziodzio T, Loewe C, Reineke D, 
Krahenbuhl E, Grimm M, Ehrlich M. Results after thoracic endovascular aortic repair  in penetrating 
atherosclerotic ulcers. Ann Thorac Surg. 2011;92:562 -567.  
72 Cooper DG, Walsh SR, Sadat U, Noorani A, Hayes PD, Boyle JR. Neurological complications after left 
subclavian artery coverage during thoracic endovascular aortic repair: a systemat ic review and meta -
analysis. J Vasc Surg. 2009 Jun;49(6):1594 -601.  
73 Peterson BG, Eskandari MK, Gleason TG, Morasch MD. Utility of left subclavian artery revascularization in 
association with endoluminal repair of acute and chronic thoracic aortic  pathology. J Vasc Surg. 2006; 
43:433 –439.  
74 Rizvi AZ, Murad MH, Fairman RM, Erwin PJ, Montori VM. The effect of left subclavian artery coverage on 
morbidity and mortality in patients undergoing endovascular thoracic aortic interventions: A systematic 
revie w and meta -analysis. J Vasc Surg. 2009; 50:1159 –1169.  
75 Matsumura JS, Rizvi AZ; Society for Vascular Surgery. Left subclavian artery revascularization: Society for 
Vascular Surgery Practice Guidelines. J Vasc Surg. 2010 Oct;52(4 Suppl):65S -70S.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 35 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 • Occlusion or absence of the right vertebral artery  
• Left arm arteriovenous shunt  
• Prior infrarenal aortic repair with ligation of the lumbar and middle sacral arteries  
• Long segment coverage of the descending thoracic aorta affecting critical 
intercostal arteries  
• Hypogastric occlusion  
• Discontinuity in the vertebrobasilar collaterals namely the termination of the left 
vertebral artery at the posterior inferior cerebellar artery  
Preoperative revascularization consists of either bypassing or tran sposing the LSA to the 
carotid artery. Additionally, the LSA is occluded or ligated in order to prevent potential 
Type II endoleaks post -TEVAR. However, subclavian revascularization is not without 
serious risks. Complications of LSA revascularization have been reported to occur in 2.4 to 
12.2% of patients. These include stroke, bleeding, injury to the thoracic duct, and left 
cervical nerves including the phrenic nerve and brachial plexus. Although most nerve 
damage is temporary, permanent defects can persis t in approximately 3% of patients.74 
Because of the potential complications and the additional surgical procedure, and despite 
the Society for Vascular Surgery practice guidelines, some physicians decide not to 
perform LSA revascularization. Often, LSA revascularization is performed when the 
patient has a dominant left vertebral artery, a previous left internal mammary coronary 
artery bypass graft (CABG), or an absent distal right vertebral segment. Alternatively, 
advances in stent graft design provide additional options for preserving patency  of the LSA 
with fenestrated, multi -branched, or the use of chimney grafts.  
A well -established procedure and materials for TEVAR provides a foundation for these 
treatment option advances. All three options require modifications to currently available 
sten t graft systems. The fenestrated device requires the operator to create fenestrations 
(i.e., holes) in the stent graft (pre -implant) in order to facilitate blood flow to the great 
vessels within the covered region. These fenestrations are secured with bare -metal or 
covered stents used as bridging stents. The multi -branch option incorporates axially 
oriented, covered stent graft cuffs to accommodate the great vessels. These stent graft 
configurations are custom -made, adding at least six to eight weeks76 betwe en evaluation 
and treatment. A hybrid approach combines stent graft cuffs positioned in the 
                                                 
76 Resch TA,  Dias NV, Sobocinski J, Sonesson B, Roeder B, Haulon S. Development of off-the -shelf stent 
grafts for juxtarenal abdominal aortic aneurysms.  Eur J Vasc Endovasc Surg. 2012 Jun;43(6):655 -60.  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 36 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 fenestrations to allow for a seal to be established within the branched artery, rather than at 
the origin, providing more flexibility for patient -specific variation s in arch morphology. The 
primary limit ation  to the advancement of this option has been in the lack of covered stent 
graft cuffs sized appropriately for the great vessels.  
A modular, off -the -shelf option needs to incorporate elements of all three techniqu es in 
order to preserve patency of the LSA and provide a more established treatment option. 
Valiant Mona LSA provides that unmet need of a singular endovascular procedure for 
disease encroaching the LSA.  The Valiant Mona LSA device provides off -the -shelf, 
branched, endograft technology to the patient, with the benefits of endovascular 
technology – namely decreased procedure time, decreased blood loss, and decreased 
mortality rates.  
An Early Feasibility study was conducted in order to provide important infor mation 
regarding the Valiant Mona LSA Thoracic Stent Graft System  in descending thoracic aortic 
aneurysms and penetrating ulcers including validation of the procedural steps and patient 
selection, an acute assessment of the safety and performance of the de vice at 1 month, 
and collection of imaging from the subjects in order to understand device movements in 
humans to augment the current use conditions data set .  
The device was successfully implanted into nine (9) subjects and continues to function as 
intend ed. Data collected from the Early Feasibility study allowed Medtronic to identify 
patient selection and implantation procedural steps that required further clarification, in 
particular t o exclude grade IV and grade V aortic atheroma anatomies and t hat 
mani pulations of the stent graft devices and accessory devices should be performed distal 
to the LSA. In order to further characterize the study device , a traditional Feasibility study 
for the Valiant Mona LSA Thoracic Stent Graft System  is necessary . The Valiant Mona LSA 
Thoracic Stent Graft System design used during the Early Feasibility study will be used for 
the Feasibility Study.  
The purpose of th e Feasibility Study i s to characterize the Valiant Mona LSA Thoracic 
Stent Graft System, in particular  to assess the safety and effectiveness of the device 
acutely and at the 30 day  visit  in the identified subject population. This study will also 
evaluate the current instructions for use and may  direct changes to the delivery and 
deployment steps.  
Initial  clinical data from the Feasibility Study suggest the measures taken to reduce post -
procedural neurological events have had a positive impact on the clinical outcomes seen in 
the subjects enrolled to date. The performance data obtained from the Early Feasi bility and 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 37 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 the Feasibility Study to date demonstrates that the Valiant Mona LSA device design is 
performing as intended.  
The positive combined safety and performance indicators reported for subjects enrolled 
under protocol version 1A  led Medtronic to purs ue an expansion to the Feasibility Study to 
gain clinical experience with chronic Type B dissection and to allow for broader investigator 
experience with the Valiant Mona LSA device. The design elements, procedural implant 
techniques, and patient selection  measures in place were deemed  appropriate to expand 
assessment of the safety and performance outcomes in subjects with chronic Type B 
dissections. The purpose of the expansion to the Feasibility Study i s to characterize the 
Valiant Mona LSA Thoracic Stent Graft System, in particular to assess the safety and 
effectiveness of the device acutely and at the 30 day visit, in subjects enrolled with chronic, 
Type B dissections. The chronic Type B Dissection exp ansion subjects will be 
prospectively enrolled in support of a future premarket approval analysis for the Valiant 
Mona LSA device . 
 
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 38 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 3. INTENDED USE OF THE DEVICE  
The Valiant Mona LSA Thoracic Stent Graft System is for the endovascular repair of 
fusiform/saccular aneurysms , type B chronic dissections,  and penetrating ulcers of the 
descending thoracic aorta (DTA) in patients who  require coverage of the left subclavian 
artery (LSA) presenting with the appropriate anatomy, including:  
• Iliac or femoral  artery access vessel morphology that is compatible with vascular 
access techniques, devices, or accessories  
• Non -diseased aortic diameter in the range of 25 mm to 42 mm  (fusiform/saccular 
aneurysm s and  penetrating ulcers ) or 28 mm to 44 mm (dissection s) 
• Non -diseased LSA diameter in the range of 8 mm to 13 mm  
• Total effective non -diseased aortic proximal neck length of ≥  20 mm between the 
distal end of LCC ostium to the beginning of the disease , including  the LSA ostium 
diameter and n on-diseased aortic neck length  ≥ 10 mm between the LSA and LCC   
• Non-aneursymal  aortic distal neck length ≥  20 mm  
• Total effective non -diseased  aortic proximal neck length of >0 mm between the 
distal end of the LSA ostium to the beginning of the disease  
 
  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 39 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 4. DESCRIPTION OF THE DEVICE   
The Valiant Mona LSA Thoracic Stent Graft  System is a modular system intended to 
maintain perfusion of the LSA when the device is implanted in Zone 2 of the aortic arch for 
the exclusion of a TAA , PAU, and CTBD . Details regarding the device design are presented 
in the following sections.  
4.1. DEVICE COMPONENTS  
The Valiant Mona LSA Thoracic Stent Graft  System is comprise d of two key components 
(See Figure 4-1):  
• The Main Stent Graft (MSG) which is delivered using the M ain Stent Graft  Delivery 
System  
• The Branch Stent Graft (BSG) which is delivered using the B ranch Stent Graft  
Delivery System  
 
Figure 4-1: Valiant Mona LSA Thoracic Stent Graft System  
Note: Graphical representation not to scale.  
 
4.2. MAIN STENT GRAFT SYSTEM  
The Main Stent Graft System is comprise d of the Main Stent Graft and the Main Delivery 
System. An overview of the Main Stent Graft System is provided below.  

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 40 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Main Stent Graft  
The Main Stent Graft (MSG) is based on the commercial Valiant Stent Graft platform  
(P100040 approved on April 1, 2011) . As shown in Table 4-2 below, the MSG includes a 
“cuff” at the proximal section of the stent graft. This cuff is used for mating of the MSG 
with the Bra nch Stent Graft (BSG).  
The MSG (with the exception of the cuff) is manufactured using monofilament polyester 
fabric and nitinol stents. The stent graft material, stent material and surface finish are 
identical to those used on the Valiant Stent Graft. The designs of all stents are also 
identical to Valiant with the exception of the two most proximal body stents and the stent 
on the cuff (Mobile External Connector [MEC] stent).  
 
. 
The cuff is intended to seal with the BSG which provides for perfusion of the LSA. This cuff 
is made using HDM polyester fabric which is identical to that used on the commercially 
available Endurant II stent graft  (P100021, approved on April 27, 2012 ). The  design of the 
cuff  
 is the same across all sizes of the MSG. The cuff contains two 
Platinum Iridium (Pt-Ir) radiopaque marker coils at the top and bott om  of the cuff to assist 
with visualization during deployment and guide placement . These coils are located within a 
fold of fabric and as such do not directly come in contact with either the BSG or the vessel. 
An additional P t-Ir marker is placed immediate ly distal to the cuff, again to assist with 
visualization and deployment accuracy. The cuff features a stent at the top, called the MEC 
Stent.  
  

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 41 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
Figure 4-2: The Main Stent Graft  
The MSG is available in diameters ranging from 30mm to 46mm with 2mm increments.  An 
overview of the MSG sizes and configurations is provided in  Table 4-3: Sizes and 
Configuration of the MSG and BSG 3.  
Table 4-1: MSG Materials  
 below lists the materials used on the MSG  including the cuff.  
Table 4-1: MSG Materials  
Component  Material  Comments  
Stents  Nitinol  Same as Valiant  
Fabric, Main Body  Monofilament Polyester  Same as Valiant  
Fabric, cuff  Multifilament (HDM) Polyester  Same as Endurant II  
Suture  Polyester  Same as Valiant  
Radiopaque markers  
(Figur e 8 and Button)  Platinum -Iridium  Same as Valiant  
Radiopaque markers (coil)  Platinum -Iridium  Same as Endurant II  
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 42 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
Main Delivery System  
The Main Delivery System (MDS) will be used to deploy the MSG . The MDS design is based 
on the commercially available Valiant Captivia Delivery System. The modifications made to 
the Valiant Captivia Delivery System include the addition of proximal and distal end 
components and features to provide pre -cannulation of th e MSG cuff with the LSA 
guidewire.  
This delivery system platform provides a mechanical advantage during deployment 
coupled with a tip capture mechanism for deployment accuracy. The modifications to the 
current Valiant Captivia Delivery System include the f ollowing:  
• a modified 4 -groove Tapered Tip assembly  
•  
• a modified End Seal Y -adapter assembly  
• a modified External Slider assembly  
• a modified Screw Gear half   
• a new Second Lumen assembly  
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 43 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
Figure 4-3: Main Delivery System (Figure not to Scale)  
 
4.3. BRANCH STENT GRAFT SYSTEM  
Branch Stent Graft  
The primary function of the Branch Stent Graft ( BSG ) is to mate with the MSG  cuff and 
perfuse the Left Subclavian Artery (LSA). The BSG is offered in 10mm, 12mm and 14mm 
diameters. All three size offerings have a 40mm length and mate with the single 10mm 
diameter  cuff opening  on the MSG . To maximize the separation resistance of the junc tion 
between the MSG and the BSG, a flared section was added to the proximal end of the 
10mm and 12mm BSG designs. This flared section is not required on the 14mm design, 
since the larger diameter forms a natural flare on either side of the cuff opening . 
The BSG is composed of a multifilament polyester graft fabric and nitinol stents. The stent 
material and surface finish are identical to those used on the commercial Valiant Stent 
Graft. The multifilament polyester material is similar to that used on the co mmercially 
available Endurant Stent Graft,  
 

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 44 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
 The sutures on the BSG are composed of Ultra High Molecular Weight 
Polyethylene (UHMWPE) which is the same base material used on commercial Endurant II 
Stent G rafts for attaching the supraren al stents to the proximal edge  of the graft. The BSG 
suture has a smaller diameter than the Endurant II suture.  
The body stent of the BSG is a helical design connected to end stents with nitinol crimps. 
The flared stent on the 10mm and 12mm is a standalone stent and is not connected t o the 
helical or end stent.  
 
 
Spherical Platinum Iridium radiopaque markers are located on both the proximal and distal 
ends of the BSG.  
 
Figure 4-4: Branch Stent Graft  
 
 
 
 
 
End Stent  

Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 45 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Table 4-2 below lists the materials used on the BSG.  
Table 4-2: BSG Materials  
Component  Material  Comments  
Stents  Nitinol  Same as Valiant  
Fabric  Polyester  Similar to Endurant  II 
Radiopaque Markers  Platinum Iridium  Same as Valiant  
Suture  UHMWPE  Similar to Endurant  II 
  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 46 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 Branch Delivery System  
The Branch Delivery System (BDS) will be used for the deployment of the BSG. The BDS 
design is based on both the commercially available Endurant II Limb and Valiant Captivia 
Delivery Systems. The distal end of the BDS is a modification of the 14Fr Endurant II Limb 
Delivery System while th e proximal end of the delivery system is leveraged from Valiant 
Captivia Closed Web Delivery System. Additionally, the Graft Cover, Tapered Tip assembly 
and Middle Member have been modified for improved kink resistance in the new use 
conditions associated with navigating into the LSA. Figure 4-5 below presents the Branch 
Delivery System.  
 
 
Figure 4-5: Branch Delivery System (Figure not to Scale)  
  
External Slider  Tapered Tip  
Middle Member & Graft Cover  Sideport Extension  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 47 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 4.4. DEVICE SIZES AND CONFIGURATIONS  
Table 4-3 presents the sizes and config urations of the MSG  and the BSG  Systems. No 
tapered configurations will be offered for the MSG or the main body portion of the BSG.  All 
MSG sizes have the same MSG cuff diameter opening of 10mm . 
Table 4-3: Sizes and Configuration of the MSG and BSG  
Component  Delivery 
System (Fr)  Proximal x Distal 
Diameter (mm)  Covered 
Length  
(mm)  Native Vessel Inner Diameter 
(mm)  
Aneurysm/ 
Penetrating Ulcer  Dissection  
Main Stent 
Graft  
 24  30x30  150  25,26,27  28 
24  32x32  150  27,28,29  29, 30  
24  34x34  157  29,30,31  31, 32  
24  36x36  158  31,32  33, 34  
24 38x38  159  33,34  35, 36  
24  40x40  161  35,36  37, 38  
25 42x42  168  37,38  39, 40  
25  44x44  170  39,40  40, 41, 42  
25  46x46  172  41,42  42, 43, 44  
Branch Stent 
Graft  15  10x10  40 8,9  
15 12x12  40 10,11  
15 14x14  40 12,13  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 48 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 5. STUDY OBJECTIVES  
5.1 STUDY PURPOSE  
The purpose of the clinical investigation  is to assess the feasibility of the Valiant Mona LSA 
Thoracic Stent Graft System  to repair fusiform/saccular aneurysms, penetrating ulcers  
and chronic type B dissections  of the DTA  in patients who require coverage  of the LSA , 
including an assessment of  the safety and effectiveness of the device acutely and at the 30 
day visit in the identified subject population. Procedural information will be collected in 
order to enhance  the current instructions for use  and  delivery and deployment steps.  
The chronic Type B Dissection expansion subjects will be prospectively enrolled in support 
of a future premarket approval analysis for the Valiant Mona LSA device . 
Patients diagnosed with  an aneurysmal descending thoracic aorta , penetrating ulcer,  or 
chronic type B dissection who meet the eligibility criteria for the study may be enrolled (see 
Section 9.1 - Eligibility Criteria) . Additionally, these patients must be candidates for 
revascularization of the LSA and anatomically appropriate for the device.  
 
5.2 SCOPE AND DURATION OF THE CLINICAL  STUDY  
Study enrollment started  in the United States in 2015. Up to ten  (10) investigational sites 
may participate. The enrollment period is estimated to be 20 months. To ensure adequate 
disease state representation in the overall stu dy dataset, a minimum of approximately 
25% of the subjects will be enrolled for the treatment of aneurysms or penetrating ulcers 
and a minimum of approximately 25% of the subjects will be enrolled for the treatment of 
chronic Type B dissections.  
Data from the 44 subjects who under go treatment with the Valiant Mona LSA Thoracic 
Stent Graft System in th is study will be analyzed and summarized in the Annual Progress 
Reports (APR) for FDA. Data collected in this study may be used to submit original 
marketing applications for approval to commercially distribute the device system.  
To permit collection of long -term safety and effectiveness data  on the stent graft system,  
subjects  will be followed for a total of 5 years  under this same clinical protocol . After the 
scheduled 12-month study visit, patients will continue to be evaluated on an annual basis  
for up to  5 years  post  implantation . When all enrolled subjects  have been followed for 5 
years post index procedure , or have exited , the study will be closed .  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 49 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 6. CLINICAL STUDY DESIGN  
This study is a p rospective, single -arm, non -randomized, multicenter, pre -market clinical 
study evaluating subjects implanted with the Valiant Mona LSA Thoracic Stent Graft 
System for the treatment of aneurysms , type B chronic dissections, and  penetrating ulcers 
of the descending thoracic aorta who  are candidates for revascularization of the left 
subclavian artery . All analyses will be descriptive in nature and no statistical comparisons 
are planned. Th is study is not a hypothesis driven study; no hypotheses testing will be 
carried out.  
There is no sample size calculation since this study  is not a hypothesis driven study; 
however, the number of enrolled subjects is pre -specified. Th is study  will enroll up to 44 
subjects.  
  
Evaluation of Valiant Mona LSA Clinical 
Investigation Plan  
 
 10151194DOC  Version  1F Page 50 of 200  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
 7.  METHODS  AND ANAL YS ES 
7.1 DESCRIPTION OF STUDY OBSERVATIONS  
7.1.1  Primary Safety Observation  
The following data points will be collected for reporting.  The initial reporting period will be 
all occurrences  within 1 month (Day 0 – Day 30) from the index procedure . The d ata will 
consist of:  
• Aorta -Related Mortality  
• Stroke  
• Paraplegia   
• Left Arm/ Hand Ischemia  
 
7.1.2  Primary Effectiveness Observation  
The primary effectiveness observation  is treatment success (defined below) and will be 
captured within the initial reporting period of  1 month from the index procedure . 
Treatment success  is defined as : 
Technical success, which is the successful delivery and deployment of the stent graft 
(deployment of the Valiant Mona LSA Thoracic Stent Graft System in the planned loca tion 
with no unintentional coverage of other vessels , assessed intra -operatively, and the 
removal of the delivery system) and successful exclusion of the aneurysm/penetrating 
ulcer or primary entry tear  while maintaining patency of the MSG and BSG at 30 day visit . 
 
7.1.3  Additional Observations  
The following additional observations  will be evaluated through the 30 day  visit  and at each 
follow up visit .  
• Major adverse events (MAEs)  rates within 30 days of the initial or secondary 
procedures, including:  
o All-Cause Mortality  
o Myocardial Infarction  
o Paraplegia  
o Renal Failure  
o Stroke  
o Left Arm/ Hand Ischemia  
• Secondary endovascular procedures  